We recently published a list of 10 Stocks Lead Friday’s Charge. In this article, we are going to take a look at where Hims & Hers Health Inc. (NYSE:HIMS) stands against other stocks that lead Friday’s ...

Cube will underpin many of the AI tools we will develop in the years to come, including highly complex scene-generation tools ...

Last month, the U.S. Food and Drug Administration (the “FDA”) announced in a Declaratory Order the resolution of the shortage of semaglutide ...

Brazilian drugmaker Hypera plans to launch next year a generic version of semaglutide, the active ingredient of Novo Nordisk's blockbuster diabetes and weight-loss drug Ozempic, Hypera's chief ...

Fact checked by Nick Blackmer “Microdosing” GLP-1 drugs like Ozempic is gaining attention on social media, but doctors say it ...

Engage in strength training a minimum of three times weekly. This can be any form of exercise that challenges your muscles. The exercises should be becoming increasingly difficult (or the weights ...

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

Novo Nordisk’s Wegovy is about to enter the Irish market but people will have to pay for it from their own pocket - for now ...

Mounjaro, Eli Lilly's diabetes and obesity drug, is now available in India at a fraction of its US price. It offers treatment for weight loss and diabetes control, but watch out for the side effects ...

The FDA wants bulk production of copycat versions of popular weight-loss drugs to stop, but telehealth companies and compounding pharmacies ...

One popular and affordable supplement that has shown some promise in helping with weight loss is berberine. In fact, some have called the supplement “nature’s Ozempic,” and with a month’s supply ...

Shares of Hims & Hers rose 7.59 percent on Wednesday to finish at $33.88 apiece as investors resorted to bargain-hunting ...